A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes

Pharmaceutical Biology

Volumn 52, Issue 2, 2014, Pages 268-271

  Kosaraju, Jayasankar ^a   Dubala, Anil ^a   Chinni, Santhivardhan ^a   Khatwal, Rizwan Basha ^a   Satish Kumar, M N ^a   Basavan, Duraiswamy ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Dipeptidyl peptidase 4; Dissociation kinetics; Enzyme inhibitory half lives; Glucagon like peptide 1

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GYMNEMA SYLVESTRE EXTRACT; KINO EXTRACT; PLANT EXTRACT; SYZYGIUM CUMINI EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG POTENCY; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; ENZYME KINETICS; GYMNEMA SYLVESTRE; IC 50; IN VITRO STUDY; IN VIVO STUDY; KINO; LEGUME; MALE; NONHUMAN; PROTEIN DETERMINATION; RAT; SYZYGIUM CUMINI;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUGENIA; GLUCAGON-LIKE PEPTIDE 1; GYMNEMA SYLVESTRE; HYPOGLYCEMIC AGENTS; INDIA; INHIBITORY CONCENTRATION 50; MALE; MEDICINE, AYURVEDIC; PLANT EXTRACTS; PTEROCARPUS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84891766932     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.823550     Document Type: Article

References (18)

1. Ahmad F, Khalid P, Khan MM, et al. (1991). Hypoglycemic activity of Pterocarpus marsupium wood. J Ethnopharmacol 35:71-5.
2. Ahmed AB, Rao AS, Rao MV. (2010). In vitro callus and in vivo leaf extract of Gymnema sylvestre stimulate beta cells regeneration and anti-diabetic activity in Wistar rats. Phytomedicine 17:1033-9.
3. Drucker DJ. (2003). Glucagon-like peptides: Regulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol 17:161-71.
4. Inzucchi SE. (2002). Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. J Am Med Assoc 287:360-72.
5. Kanetkar P, Singhal R, Kamat M. (2007). Gymnema sylvestra: A memoir. J Clin Biochem Nutr 41:77-81.
6. Kikkawa F, Kajiyama H, Shibata K, et al. (2005). Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751:45-51.
7. Lindsay JR, Duffy NA, McKillop AM, et al. (2005). Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 22:654-7.
8. Manish D, Arun N, Ansari SH. (2009). Pterocarpus marsupium Roxb.-A comprehensive review. Phcog Rev 3:359-63.
9. Manjeshwar SB, Harshith PB, Bantwal RVB, et al. (2011). Phytochemistry, traditional uses and pharmacology of Eugenia jambolana Lam. (black plum): A review. Food Res Int 44:1776-89.
10. Michel MC, Fliers E, Van Noorden CJ. (2008). Dipeptidyl peptidase IV inhibitors in diabetes: More than inhibition of glucagon-like peptide-1 metabolism? Naunyn Schmiedebergs Arch Pharmacol 377:205-7.
11. Ng VWS, Kong APS. (2007). Dipeptidyl peptidase (DPP)-IV inhibitor: A novel class of oral anti-hyperglycemic agents. Drug Rev 12:33-4.
12. Nigel U, David W, Leonor G, et al. (2011). The IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation.
13. Perry T, Greig NH. (2002). The glucagon-like peptides: A new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 4:487-96.
14. Ravi K, Rajasekaran S, Subramanian S. (2005). Antihyperlipidemic effect of Eugenia jambolana seed kernel on streptozotocin-induced diabetes in rats. Food Chem Toxicol 43:1433-9.
15. Rosenstock J, Zinman B. (2007). Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 14:98-107.
16. Sharma B, Balomajumder C, Roy P. (2008). Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food Chem Toxicol 46:2376-83.
17. Thomas L, Eckhardt M, Langkopf E, et al. (2008). (R)-8-(3-Amino- piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-82.
18. Yamazaki K, Yasuda N, Inoue T, et al. (2006). 7-But-2-ynyl-9-(6-methoxy- pyridin-3-yl)-6-piperazin-1-yl-7, 9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 319: 1253-7.